Ovarian Cancer Drugs Market to Grow at An Impressive Rate Through 2027
Increasing occurrence
of ovarian cancer is expected to drive the
growth of global ovarian cancer drugs market in the forecast period, 2023-2027.
According to TechSci Research report, “Ovarian Cancer Drugs Market - Global Industry Size,
Share, Trends, Opportunity, and Forecast, 2017-2027”, the global ovarian cancer drugs market is anticipated to grow at an
impressive rate during the forecast period, 2023-2027. This can be
ascribed to the growing incidence of ovarian cancer worldwide. According to
global cancer observatory, around 313,959 new cases of ovarian cancer were reported
worldwide in 2020, with 207,252 reported deaths. This has in turn increased the
demand for different drugs required for the treatment of ovarian cancer,
thereby driving the market growth. Additionally, patent expiry of several
leading drugs used in the treatment of ovarian cancer is expected to create
lucrative opportunities for the market growth by creating room for the entry of
generic drugs manufacturers in the space. Furthermore, continuous research
& development to produce efficient therapeutic intervention for numerous
diseases boost the ovarian cancer drugs market. Many drugs are in different
phases of clinical trials and can be expected soon in the market.
However, it is most likely anticipated
that the lack of accurate early-stage diagnostic tools for ovarian cancer will
further restrain the market for ovarian cancer drugs in the years to come. Additionally,
stringent regulatory scenario in terms of drug application fillings and
approvals is expected to slow down the market growth in the coming years.
Browse
over XX market data Figures spread through 110
Pages and an in-depth TOC on "OVARIAN CANCER DRUGS MARKET"
The
global ovarian cancer drugs market is segmented into by drug class, by tumor
type, by distribution channel and by region.
Based on tumor type, the ovarian cancer drugs
market can be categorized into epithelial ovarian cancer, ovarian low malignant
potential tumor, germ cell tumor and sex cord-stromal tumor. The epithelial
ovarian cancer segment is expected to dominate the market during the forecast
period. This can be ascribed to the fact that this is the most commonly
observed ovarian cancer type worldwide.
Around 90% of ovarian tumors are epithelial.
Based on distribution channel, the global
ovarian cancer drugs market can be segmented hospital pharmacies, retail
pharmacies and online pharmacies. The hospital pharmacies segment dominated the
market in 2021 on account of easy availability of different ovarian cancer
drugs in the hospital pharmacies.
Based on region,
because of the rising ovarian cancer incidences, North
America currently dominates the ovarian cancer drug market. The expansion of
the ovarian cancer drugs market in the region will also be aided by the
introduction of new products, increased adoption of novel therapies, and a
sizable target population throughout the forecast period.
Major operating companies operating in
global ovarian cancer drugs market are:
- AstraZeneca, Plc.
- GlaxoSmithKline, Plc.
- Merck & Co.
- Clovis Oncology, Inc.
- F. Hoffmann-La Roche AG
- Bristol-Myers Squibb Co.
- Eli Lilly and Company
- Amgen Inc.
- C.H. Boehringer Sohn Ko. KG
- Novartis AG
DOWNLOAD FREE SAMPLE REPORT
Customers can also request for 10% free customization on this report.
“Asia Pacific region is expected to register the
highest growth in global ovarian cancer drugs market during the forecast period
on account of growing incidence of the cancer especially in countries like
China, India, Japan, among others. Additionally, increasing drug development
and discovery related to ovarian cancer drugs and increasing number of clinical
trials launched for the development of ovarian cancer drugs especially in
countries like China and India is expected to create lucrative opportunities
for the market growth through 2027.” said Mr. Karan Chechi, Research Director
with TechSci Research, a research based global management consulting firm.
“Ovarian
Cancer Drugs Market - Global Industry Size, Share, Trends, Opportunity, and
Forecast, 2017-2027 Segmented By Drug Class (Alkylating Agents, Mitotic Inhibitors, Antirheumatics,
Antipsoriatics, VEGF/VEGFR Inhibitors, PARP Inhibitors, Antineoplastics, Others), By Tumor Type ( Epithelial
Ovarian Cancer, Ovarian Low Malignant Potential Tumor, Germ Cell Tumor, Sex
Cord-Stromal Tumor), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online
Pharmacies) and By Region”, has evaluated the future growth potential of global ovarian cancer
drugs market and provides statistics & information on market size,
structure, and future market growth. The report intends to provide cutting-edge
market intelligence and help decision makers take sound investment decisions.
Besides, the report also identifies and analyzes the emerging trends along with
essential drivers, challenges, and opportunities in global ovarian cancer drugs
market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: https://www.techsciresearch.com